Abstract
Purpose
Antibodies form an important class of cancer therapeutics, and there is intense interest in using them for imaging applications in diagnosis and monitoring of cancer treatment. Despite the expanding body of knowledge describing pharmacokinetic and pharmacodynamic interactions of antibodies in vivo, discrepancies remain over the effect of antigen expression level on tumoral uptake with some reports indicating a relationship between uptake and expression and others showing no correlation.
Procedures
Using a cell line with high epithelial cell adhesion molecule expression and moderate epidermal growth factor receptor expression, fluorescent antibodies with similar plasma clearance were imaged in vivo. A mathematical model and mouse xenograft experiments were used to describe the effect of antigen expression on uptake of these high-affinity antibodies.
Results
As predicted by the theoretical model, under subsaturating conditions, uptake of the antibodies in such tumors is similar because localization of both probes is limited by delivery from the vasculature. In a separate experiment, when the tumor is saturated, the uptake becomes dependent on the number of available binding sites. In addition, targeting of small micrometastases is shown to be higher than larger vascularized tumors.
Conclusions
These results are consistent with the prediction that high affinity antibody uptake is dependent on antigen expression levels for saturating doses and delivery for subsaturating doses. It is imperative for any probe to understand whether quantitative uptake is a measure of biomarker expression or transport to the region of interest. The data provide support for a predictive theoretical model of antibody uptake, enabling it to be used as a starting point for the design of more efficacious therapies and timely quantitative imaging probes.
Similar content being viewed by others
Abbreviations
- EGFR:
-
Epidermal Growth Factor Receptor
- EpCAM:
-
Epithelial Cell Adhesion Molecule
- VT680:
-
VivoTag 680 fluorescent dye
- AF750:
-
AlexaFluor 750 fluorescent dye
References
Li WP, Meyer LA, Capretto DA, Sherman CD, Anderson CJ (2008) Receptor-binding, biodistribution, and metabolism studies of Cu-64-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm 23:158–171
Zhao BS, Schwartz LH, Larson SM (2009) Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med 50:239–249
McLarty K, Cornelissen B, Cai ZL, Scollard DA, Costantini DL, Done SJ, Reilly RM (2009) Micro-SPECT/CT with In-111-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 50:1340–1348
Zhang YJ, Xiang LM, Hassan R, Pastan I (2007) Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci USA 104:17099–17104
Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137–1146
Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, Horak ID, Goldenberg DM (2005) Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 11:7109S–7121S
Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM (2008) Therapy of advanced B-lymphoma xenografts with a combination of Y-90-anti-CD22 IgG (Epratuzumab) and unlabeled Anti-CD20 IgG (Veltuzumab). Clin Cancer Res 14:6154–6160
Thurber G, Figueiredo J, Weissleder R (2009) Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model. Plos One 4:e8053
Zou P, Xu SB, Povoski SP, Wang A, Johnson MA, Martin EW, Subramaniam V, Xu R, Sun DX (2009) Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm 6:428–440
Urano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M, Nagano T, Watanabe T, Hasegawa A, Choyke PL et al (2009) Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 15:104–109
Rosenthal EL, Kulbersh BD, King T, Chaudhuri TR, Zinn KR (2007) Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther 6:1230–1238
Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G et al (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94:1484–1493
Stollman TH, Scheer MGW, Franssen GM, Verrijp KN, Oyen WJG, Ruers TJM, Leenders WPJ, Boerman OC (2009) Tumor Accumulation of radiolabeled bevacizumab due to targeting of cell- and matrix-associated VEGF-A isoforms. Cancer Biother Radiopharm 24:195–200
Wu AM, Olafsen T (2008) Antibodies for molecular imaging of cancer. Cancer J 14:191–197
Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM (2006) Early tumor response to Hsp90 therapy using HER2 PET: comparison with F-18-FDG PET. J Nucl Med 47:793–796
Cai WB, Chen K, He LN, Cao QH, Koong A, Chen XY (2007) Quantitative PET of EGFR expression in xenograft-bearing mice using Cu-64-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34:850–858
McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM (2009) Associations between the uptake of In-111-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 36:81–93
Aerts H, Dubois L, Perk L, Vermaelen P, van Dongen G, Wouters BG, Lambin P (2009) Disparity between In vivo EGFR expression and Zr-89-labeled cetuximab uptake assessed with PET. J Nucl Med 50:123–131
Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW (2008) Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 23:619–631
Niu G, Li Z, Xie J, Le Q-T, Chen X (2009) PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 50:1116–1123
Thurber G, Schmidt M, Wittrup KD (2008) Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29:57–61
Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60:1421–1434
Thurber GM, Wittrup KD (2008) Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res 68:3334–3341
Thurber GM, Zajic SC, Wittrup KD (2007) Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 48:995–999
Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8:2861
Mager DE (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72:1–10
Adams G, Schier R, McCall A, Simmons H, Horak E, Alpaugh K, Marks J, Weiner L (2001) High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res 61:4750–4755
Ackerman ME, Chalouni C, Schmidt MM, Raman VV, Ritter G, Old LJ, Mellman I, Wittrup KD (2008) A33 antigen displays persistent surface expression. Cancer Immunol Immunother 57:1017–1027
Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H (1998) Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89:307–314
Sharkey RM, Natale A, Goldenberg DM, Mattes MJ (1991) Rapid blood clearance of immunoglobulin-G2A and immunoglobulin-G2B in nude-mice. Cancer Res 51:3102–3107
Lonsmann H (1974) Interstitial fluid concentrations of albumin and immunoglobulin-G in normal men. Scand J Clin Lab Invest 34:119–122
Wiig H, Gyenge CC, Tenstad O (2005) The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. J Physiol-London 567:557–567
Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437:497–504
Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765–14770
Maxwell JL, Terracio L, Borg TK, Baynes JW, Thorpe SR (1990) A fluorescent residualizing label for studies on protein-uptake and catabolism in vivo and in vitro. Biochem J 267:155–162
Ferl GZ, Kenanova V, Wu AM, DiStefano JJ (2006) A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 5:1550–1558
Sung C, Youle RJ, Dedrick RL (1990) Pharmacokinetic analysis of immunotoxin uptake in solid tumors—role of plasma kinetics, capillary-permeability, and binding. Cancer Res 50:7382–7392
Ahlstrom H, Christofferson R, Lorelius L (1988) Vascularization of the continuous human colonic cancer cell line LS 174 T deposited subcutaneously in nude rats. APMIS 96:701–710
Flynn A, Boxer G, Begent R, Pedley R (2001) Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images. Cancer Immunol Immunother 50:77–81
Baxter L, Jain RK (1989) Transport of fluid and macromolecules in tumors: 1. Role of interstitial pressure and convection. Microvasc Res 37:77–104
Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM (2007) Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 179:2815–2823
Hilmas D, Gillette E (1974) Morphometric analyses of the microvasculature of tumors during growth and after X-irradiation. Cancer 33:103–110
Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170(4):974–980, Mosby-Year Book Inc
Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22:701–706
Acknowledgments
This work was supported by grants P50 CA86355, U24 CA092782, and T32 CA079443.
Conflict of Interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
ESM 1
(PDF 7024 kb)
Rights and permissions
About this article
Cite this article
Thurber, G.M., Weissleder, R. Quantitating Antibody Uptake In Vivo: Conditional Dependence on Antigen Expression Levels. Mol Imaging Biol 13, 623–632 (2011). https://doi.org/10.1007/s11307-010-0397-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-010-0397-7